Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review
Abstract Background Transarterial radioembolization (TARE) with yttrium-90 microspheres is a clinically effective therapy for hepatocellular carcinoma (HCC) treatment. This study aimed to perform a systematic review of the available economic evaluations of TARE for the treatment of HCC. Methods The...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-07-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12876-022-02396-6 |
| _version_ | 1818470948066557952 |
|---|---|
| author | J. C. Alonso I. Casans F. M. González D. Fuster A. Rodríguez N. Sánchez I. Oyagüez R. Burgos A. O. Williams N. Espinoza |
| author_facet | J. C. Alonso I. Casans F. M. González D. Fuster A. Rodríguez N. Sánchez I. Oyagüez R. Burgos A. O. Williams N. Espinoza |
| author_sort | J. C. Alonso |
| collection | DOAJ |
| description | Abstract Background Transarterial radioembolization (TARE) with yttrium-90 microspheres is a clinically effective therapy for hepatocellular carcinoma (HCC) treatment. This study aimed to perform a systematic review of the available economic evaluations of TARE for the treatment of HCC. Methods The Preferred Reported Items for Systematic reviews and Meta-Analyses guidelines was followed by applying a search strategy across six databases. All studies identified as economic evaluations with TARE for HCC treatment in English or Spanish language were considered. Costs were adjusted using the 2020 US dollars based on purchasing-power-parity ($US PPP). Results Among 423 records screened, 20 studies (6 cost-analyses, 3 budget-impact-analyses, 2 cost-effectiveness-analyses, 8 cost-utility-analyses, and 1 cost-minimization analysis) met the pre-defined criteria for inclusion. Thirteen studies were published from the European perspective, six from the United States, and one from the Canadian perspectives. The assessed populations included early- (n = 4), and intermediate-advanced-stages patients (n = 15). Included studies were evaluated from a payer perspective (n = 20) and included both payer and social perspective (n = 2). TARE was compared with transarterial chemoembolization (TACE) in nine studies or sorafenib (n = 11). The life-years gained (LYG) differed by comparator: TARE versus TACE (range: 1.3 to 3.1), and TARE versus sorafenib (range: 1.1 to 2.53). Of the 20 studies, TARE was associated with lower treatment costs in ten studies. The cost of TARE treatment varied widely according to Barcelona Clinic Liver Cancer (BCLC) staging system and ranged from 1311 $US PPP/month (BCLC-A) to 71,890 $US PPP/5-years time horizon (BCLC-C). The incremental cost-utility ratio for TARE versus TACE resulted in a 17,397 $US PPP/Quality-adjusted-Life-Years (QALY), and for TARE versus sorafenib ranged from dominant (more effectiveness and lower cost) to 3363 $US PPP/QALY. Conclusions Economic evaluations of TARE for HCC treatment are heterogeneous. Overall, TARE is a cost-effective short- and long-term therapy for the treatment of intermediate-advanced HCC. |
| first_indexed | 2024-04-13T21:44:23Z |
| format | Article |
| id | doaj.art-53837ac4e62c4c35ac4e7afc87b1ebfb |
| institution | Directory Open Access Journal |
| issn | 1471-230X |
| language | English |
| last_indexed | 2024-04-13T21:44:23Z |
| publishDate | 2022-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj.art-53837ac4e62c4c35ac4e7afc87b1ebfb2022-12-22T02:28:38ZengBMCBMC Gastroenterology1471-230X2022-07-0122112310.1186/s12876-022-02396-6Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic reviewJ. C. Alonso0I. Casans1F. M. González2D. Fuster3A. Rodríguez4N. Sánchez5I. Oyagüez6R. Burgos7A. O. Williams8N. Espinoza9Nuclear Medicine Department, Hospital Gregorio MarañónNuclear Medicine Department, Hospital Clínico UniversitarioNuclear Medicine Department, Hospital Universitario CentralNuclear Medicine Department, Hospital ClinicNuclear Medicine Department, Hospital Virgen de las NievesNuclear Medicine Department, Hospital ClinicPharmacoeconomics & Outcomes Research Iberia (PORIB)Boston Scientific IberiaBoston ScientificPharmacoeconomics & Outcomes Research Iberia (PORIB)Abstract Background Transarterial radioembolization (TARE) with yttrium-90 microspheres is a clinically effective therapy for hepatocellular carcinoma (HCC) treatment. This study aimed to perform a systematic review of the available economic evaluations of TARE for the treatment of HCC. Methods The Preferred Reported Items for Systematic reviews and Meta-Analyses guidelines was followed by applying a search strategy across six databases. All studies identified as economic evaluations with TARE for HCC treatment in English or Spanish language were considered. Costs were adjusted using the 2020 US dollars based on purchasing-power-parity ($US PPP). Results Among 423 records screened, 20 studies (6 cost-analyses, 3 budget-impact-analyses, 2 cost-effectiveness-analyses, 8 cost-utility-analyses, and 1 cost-minimization analysis) met the pre-defined criteria for inclusion. Thirteen studies were published from the European perspective, six from the United States, and one from the Canadian perspectives. The assessed populations included early- (n = 4), and intermediate-advanced-stages patients (n = 15). Included studies were evaluated from a payer perspective (n = 20) and included both payer and social perspective (n = 2). TARE was compared with transarterial chemoembolization (TACE) in nine studies or sorafenib (n = 11). The life-years gained (LYG) differed by comparator: TARE versus TACE (range: 1.3 to 3.1), and TARE versus sorafenib (range: 1.1 to 2.53). Of the 20 studies, TARE was associated with lower treatment costs in ten studies. The cost of TARE treatment varied widely according to Barcelona Clinic Liver Cancer (BCLC) staging system and ranged from 1311 $US PPP/month (BCLC-A) to 71,890 $US PPP/5-years time horizon (BCLC-C). The incremental cost-utility ratio for TARE versus TACE resulted in a 17,397 $US PPP/Quality-adjusted-Life-Years (QALY), and for TARE versus sorafenib ranged from dominant (more effectiveness and lower cost) to 3363 $US PPP/QALY. Conclusions Economic evaluations of TARE for HCC treatment are heterogeneous. Overall, TARE is a cost-effective short- and long-term therapy for the treatment of intermediate-advanced HCC.https://doi.org/10.1186/s12876-022-02396-6CarcinomaHepatocellularLiver neoplasmsRadiotherapyYttrium-90Cost |
| spellingShingle | J. C. Alonso I. Casans F. M. González D. Fuster A. Rodríguez N. Sánchez I. Oyagüez R. Burgos A. O. Williams N. Espinoza Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review BMC Gastroenterology Carcinoma Hepatocellular Liver neoplasms Radiotherapy Yttrium-90 Cost |
| title | Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review |
| title_full | Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review |
| title_fullStr | Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review |
| title_full_unstemmed | Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review |
| title_short | Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review |
| title_sort | economic evaluations of radioembolization with itrium 90 microspheres in hepatocellular carcinoma a systematic review |
| topic | Carcinoma Hepatocellular Liver neoplasms Radiotherapy Yttrium-90 Cost |
| url | https://doi.org/10.1186/s12876-022-02396-6 |
| work_keys_str_mv | AT jcalonso economicevaluationsofradioembolizationwithitrium90microspheresinhepatocellularcarcinomaasystematicreview AT icasans economicevaluationsofradioembolizationwithitrium90microspheresinhepatocellularcarcinomaasystematicreview AT fmgonzalez economicevaluationsofradioembolizationwithitrium90microspheresinhepatocellularcarcinomaasystematicreview AT dfuster economicevaluationsofradioembolizationwithitrium90microspheresinhepatocellularcarcinomaasystematicreview AT arodriguez economicevaluationsofradioembolizationwithitrium90microspheresinhepatocellularcarcinomaasystematicreview AT nsanchez economicevaluationsofradioembolizationwithitrium90microspheresinhepatocellularcarcinomaasystematicreview AT ioyaguez economicevaluationsofradioembolizationwithitrium90microspheresinhepatocellularcarcinomaasystematicreview AT rburgos economicevaluationsofradioembolizationwithitrium90microspheresinhepatocellularcarcinomaasystematicreview AT aowilliams economicevaluationsofradioembolizationwithitrium90microspheresinhepatocellularcarcinomaasystematicreview AT nespinoza economicevaluationsofradioembolizationwithitrium90microspheresinhepatocellularcarcinomaasystematicreview |